Form 8-K · Current report
Dexcom 8-K, filed Oct 29, 2026
- Filed
- CIK
- 0001093557
- Accession no.
- 0001093557-26-000193
Summary
Dexcom reported third-quarter 2026 revenue of $1.344 billion, up 11% year-over-year, raised its full-year 2026 revenue and margin guidance, and announced a share repurchase program of up to $1.0 billion authorized by its board. The company also said the CONNECT randomized clinical trial of its G7 continuous glucose monitor in people with Type 2 diabetes not on insulin was published in The New England Journal of Medicine, and it launched a redesigned Stelo experience.
Key points
- Dexcom's third-quarter 2026 GAAP operating income was $327.2 million, or 24.3% of revenue, up 420 basis points year-over-year, with GAAP net income of $275.1 million, or $0.72 per diluted share.
- Full-year 2026 guidance was raised to revenue of $5.20-$5.25 billion, roughly 64% non-GAAP gross margin, about 24% non-GAAP operating margin, and about 32% adjusted EBITDA margin.
- The share repurchase program runs through no later than December 31, 2027 and does not obligate Dexcom to repurchase any set amount.
- President and CEO Jake Leach said the quarter's performance allowed the company to again raise full-year revenue and operating margin guidance.
- Dexcom said it advanced the U.S. rollout of the G7 15 Day System and secured its first two international regulatory clearances for it.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 8.01Other Events
- 9.01Financial Statements and Exhibits
From the filing
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On October 29, 2026, DexCom, Inc. (“Dexcom”) issued a press release announcing its financial results for the quarter ended September 30, 2026 and certain other information. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.